NYSE:LLYPharmaceuticals
Eli Lilly (LLY) Stock Valuation After New Obesity And Dermatology Drug Milestones
Eli Lilly (LLY) stock has been moving on a flurry of early June catalysts, including strong late stage data for obesity drug retatrutide, progress for oral GLP-1 Foundayo, and an FDA-approved, less frequent Ebglyss regimen.
See our latest analysis for Eli Lilly.
The recent clinical and regulatory news flow is feeding into strong momentum, with Eli Lilly’s 30 day share price return of 17.28% sitting against a 1 year total shareholder return of 43.98% and a very large 5 year total shareholder...